Emergent Biosolutions, Inc. (EBS) Stake Decreased by Acadian Asset Management LLC

Acadian Asset Management LLC reduced its position in Emergent Biosolutions, Inc. (NYSE:EBS) by 11.7% during the second quarter, Holdings Channel reports. The fund owned 1,236,678 shares of the biopharmaceutical company’s stock after selling 163,413 shares during the period. Acadian Asset Management LLC’s holdings in Emergent Biosolutions were worth $41,935,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of EBS. Aperio Group LLC boosted its position in Emergent Biosolutions by 5.3% in the second quarter. Aperio Group LLC now owns 11,644 shares of the biopharmaceutical company’s stock worth $395,000 after buying an additional 589 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in Emergent Biosolutions by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 14,200 shares of the biopharmaceutical company’s stock worth $482,000 after buying an additional 100 shares in the last quarter. Eqis Capital Management Inc. boosted its position in Emergent Biosolutions by 0.7% in the second quarter. Eqis Capital Management Inc. now owns 38,382 shares of the biopharmaceutical company’s stock worth $1,302,000 after buying an additional 271 shares in the last quarter. State of Alaska Department of Revenue boosted its position in Emergent Biosolutions by 79.9% in the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the biopharmaceutical company’s stock worth $232,000 after buying an additional 3,051 shares in the last quarter. Finally, Creative Planning boosted its position in Emergent Biosolutions by 1.2% in the second quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 55 shares in the last quarter. Institutional investors own 85.86% of the company’s stock.

Emergent Biosolutions, Inc. (NYSE:EBS) traded up 1.00% on Friday, reaching $36.41. The company’s stock had a trading volume of 202,269 shares. The firm has a market cap of $1.49 billion, a PE ratio of 28.94 and a beta of 1.21. Emergent Biosolutions, Inc. has a 52-week low of $24.47 and a 52-week high of $36.74. The stock’s 50 day moving average price is $34.00 and its 200 day moving average price is $31.13.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by $0.08. Emergent Biosolutions had a net margin of 10.36% and a return on equity of 11.92%. The business had revenue of $116.90 million during the quarter, compared to analysts’ expectations of $121.30 million. During the same period in the previous year, the business earned $0.16 EPS. The business’s revenue was up 13.5% on a year-over-year basis. Equities research analysts expect that Emergent Biosolutions, Inc. will post $1.58 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “[[title]]” was reported by [[site]] and is the property of of [[site]]. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at [[permalink]].

A number of research analysts have issued reports on the company. Zacks Investment Research cut Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Emergent Biosolutions currently has a consensus rating of “Buy” and a consensus target price of $39.25.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 25,000 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $36.50, for a total value of $912,500.00. Following the sale, the chairman now owns 1,630,216 shares of the company’s stock, valued at approximately $59,502,884. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 16.50% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).